新锐医药(06108.HK)预计上半年亏损不多于800万港元继续停牌
格隆汇8月2日丨新锐医药(06108.HK)公布,直至公告日期,独立董事委员会对有关该等收购事项的事宜的调查仍在进行。公司亦正寻求法律意见以处理及解决证监会关注之事项,进而恢复股份之买卖。然而,由于受到香港法例第571章《证券及期货条例》法定保密义务之规限,公司无法披露有关详情。鉴于各种情况,公司无法于当前阶段制定任何订有明确时限之实际可行的恢复买卖计划。公司将继续寻求法律意见以尽快恢复股份之买卖。
预期集团于2019年上半年将录得亏损,而集团于2018年同期则录得净溢利约1420万港元,主要由于收益及毛利主要因该产品销售下滑而大幅减少。根据对公司最新可得未经审核综合财务资料的进一步审阅及分析,预期集团于2019年上半年将录得亏损不多于800万港元。
此外,公司股份继续停牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.